Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of abaloparatide tablet in China. Welcome to wholesale bulk high quality abaloparatide tablet for sale here from our factory. Good service and reasonable price are available.
The Abaloparatide tablet is a synthetic peptide-based drug, acting as a similar substance to Parathyroid Hormone-related Protein (PTHrP), and is used to treat osteoporosis. Its mechanism involves selectively activating the osteogenic pathway of the Parathyroid Hormone 1 receptor (PTH1R), promoting bone formation, increasing bone density and strength, and reducing the risk of fractures.This drug is suitable for post-menopausal women and male patients with high-risk fracture risk and osteoporosis. It is taken orally once a day. Compared to traditional injection forms (such as Abaloparatide subcutaneous injection), the tablets improve the convenience of medication administration. Common side effects include dizziness, nausea, palpitations and hypercalcemia, and monitoring of blood calcium levels is required. Contraindications include bone malignancies, abnormal parathyroid function and allergies to the ingredients.
|
|
|
Abaloparatide COA
Basic Information and Development Background of the Drug
It is a 34-amino-acid polypeptide synthesized artificially and belongs to the analog of parathyroid hormone-related protein (PTHrP). It selectively activates the parathyroid hormone type 1 receptor (PTH1R) to regulate bone metabolism and promote bone formation, and is mainly used for the treatment of post-menopausal osteoporosis.
This drug was initially developed by the French Ipsen Pharmaceutical Company and licensed to the American Radius Health Biopharmaceutical Company for development. It was approved for marketing by the US Food and Drug Administration (FDA) on April 28, 2017, and is sold under the trade name Tymlos.
Manufacturing Process and Core Technology
Peptide Synthesis Method
The preparation of it mainly adopts the solid-phase fragment condensation method or the sequential synthesis method. The solid-phase fragment condensation method requires connecting the peptide resin fragments, but it has the problems of complex process and high cost. The sequential synthesis method uses amino resin as the carrier, coupling the protected amino acids from the C-terminus to the N-terminus one by one, and finally obtaining Abaloparatide resin. This method uses Boc and Fmoc protecting groups, and the process is simple, with a total yield of over 50% and a purity of over 98%.
Key Process Steps
Coupling Reaction: The protected amino acids are coupled with the resin or peptide resin through condensing reagents (such as DIC, DCC) and activating reagents (such as HOBt, HOAt). The molar ratio is preferably 1.2-6:1, and the reaction time is 60-300 minutes.
Deprotection: The N-terminal Fmoc protecting group is removed using a mixture of piperidine/DMF, with a time of 10-60 minutes.
Acidolysis and Purification: The resin is acidolysed using a mixed acidolysis solution such as trifluoroacetic acid (TFA), and then purified by high-performance liquid chromatography (HPLC), ultimately obtaining high-purity it.
Quality Control
During the manufacturing process, the content of impurities must be strictly controlled. The total impurity should be less than 2.0%, and the single impurity should be less than 0.15%. After purification, the product needs to undergo acetic acid salt replacement and be obtained through freeze-drying to obtain the final product.
Challenges in Formulation Development and Production
Development of Tablets
The original formulation of it is a subcutaneous injection. The development of tablets needs to address issues such as the stability of the peptide in the gastrointestinal tract, bioavailability, and first-pass effect. Currently, the research focus includes:
Stabilizer screening: By adding sugars (such as mannitol), amino acids, or polymers (such as hydroxypropyl methylcellulose), the stability of the peptide can be improved.
Formulation process optimization: The use of dry granulation, freeze-drying, etc. can improve the disintegration performance and solubility of the tablets.
Coating technology: Through film coating, the release rate of the drug can be controlled, reducing gastrointestinal irritation.
Production equipment and conditions
Synthesis equipment: Large-scale peptide synthesis instruments, imported HPLC analysis and preparation equipment are required.
Clean laboratory: A clean laboratory that complies with GMP standards to ensure the aseptic production environment.
Low-temperature storage: Raw materials need to be freeze-dried at -20℃ and stored in a dark place to prevent degradation.
Formulation innovation
In addition to tablets, new formulations such as transdermal patches and long-acting injectables of it are under development to further improve patient compliance and treatment efficacy.
Combination therapy
Combined use with anti-resorptive drugs (such as bisphosphonates, denosumab) can simultaneously inhibit bone resorption and promote bone formation, providing a new strategy for the treatment of osteoporosis.
Indication expansion
In addition to post-menopausal osteoporosis, the potential of it in male osteoporosis, glucocorticoid-induced osteoporosis, etc. is being explored.
Molecular Structure and Chemical Properties
It is a polypeptide composed of 34 amino acids, with the molecular formula C₁₇₄H₃₀₀N₅₆O₄₉ and a molecular weight of approximately 3960.59 g/mol. Its amino acid sequence is highly similar to that of the natural parathyroid hormone-related protein (PTHrP), but through the optimization of key regions, its selectivity for the PTH1 receptor (PTHR1) has been significantly enhanced. This selective activation mechanism can more precisely regulate the bone metabolism signaling pathway and reduce the side effects on non-bone tissues.
Physical and Chemical Properties
Appearance and Solubility
Appearance: White to off-white solid powder
Solubility:
Solubility in water ≥ 100 mg/mL (25.25 mM)
Solubility in dimethyl sulfoxide (DMSO) is 25 mg/mL (requires ultrasonic assistance for dissolution)
Stability and Storage Conditions
It needs to be freeze-dried at -20℃ and stored in a dark place to prevent degradation.
Hygroscopicity: DMSO may affect solubility, and it is recommended to use freshly opened solvent.
Pharmacological Mechanism
Activation of Gs/cAMP Signaling Pathway
After Abaloparatide tablet binds to PTHR1, it promotes the generation of cyclic adenosine monophosphate (cAMP) by activating the Gs protein, thereby regulating osteoblast proliferation, differentiation, and bone matrix mineralization. This process is manifested as an increase in trabecular bone thickness and strengthening of the cortical bone structure in animal experiments.
Enhancement of β-arrestin recruitment
This drug also promotes the recruitment of β-arrestin protein, participating in receptor desensitization and intracellular signal regulation, forming a dual regulatory mechanism. This characteristic enables it to achieve efficient bone formation stimulation at low doses, while reducing the risk of hypercalcemia.
Regulation of Bone Metabolism Balance
Compared with Teriparatide, it has a weaker stimulating effect on bone resorption and can more precisely promote bone formation, thereby increasing bone density while reducing bone microstructure damage.
Clinical Application Properties
Indications and Usage
It is approved for the treatment of postmenopausal osteoporosis, especially for patients with a high risk of fractures or those who are ineffective to other therapies.
The recommended dose of the subcutaneous injection formulation (Tymlos®) is 80 μg/day, and it is necessary to strictly follow the dosing schedule to maintain efficacy.
The development of tablets needs to solve problems such as the stability of the peptide in the gastrointestinal tract, bioavailability, and first-pass effect. It is currently in the research stage.
Safety and Side Effects
Cardiovascular Safety: Clinical trials have confirmed that Abaloparatide tablet does not increase the risk of major cardiovascular adverse events (MACE) or heart failure, but may cause transient heart rate acceleration and a slight decrease in blood pressure.
Bone Tumor Risk: Animal experiments show that long-term use of high doses (≥10 μg/kg/day) may increase the incidence of osteosarcoma, but the human relevance is not yet clear.
Common Adverse Reactions: Injection site redness (12%), headache (8%), nausea (5%), mostly mild and reversible.
Drug Interactions
Sequential use with bisphosphonate drugs (such as alendronate) can prolong efficacy and reduce the risk of fractures.
Avoid using simultaneously with anti-osteoclastic drugs (such as denosumab), which may weaken the bone formation stimulating effect.
Challenges in Research and Production
Complexity of Synthesis Process
Solid-phase fragment coupling method requires connecting multiple peptide resin fragments, but the freeze-drying process and the use of expensive resins (such as 2-CTC resin) result in high costs.
One-step synthesis method can increase the total yield to over 50% and the purity to 98% by optimizing protecting groups and coupling reagents, but the process steps are cumbersome.
Formulation Optimization Requirements
The current injection formulation has problems such as inconvenience of use and low patient compliance. The development of tablets needs to solve the following problems:
Stabilizer Screening: Add sugars (such as mannitol), amino acids, or polymers (such as hydroxypropyl methylcellulose) to improve the stability of the peptide.
Formulation Process Optimization: Use dry granulation, freeze-drying, etc. to improve the disintegration performance and solubility of the tablets.
Coating Technology: Use film coating to control the release rate of the drug and reduce gastrointestinal irritation.aloparatide has a differentiated competitive advantage due to its higher bone synthesis activity and lower incidence of hypercalcemia.
Potential Application of the product in the Prevention and Treatment of Cancer-Related Bone Loss
At present, the application of it in this field still has many limitations: first, there is a lack of large-scale, multicenter phase III clinical trial data, resulting in insufficient evidence-based medical evidence for the drug's efficacy and safety; second, the combined medication regimen with anti-tumor drugs has not been clarified, and the mechanism of drug-drug interaction needs further elucidation; third, the applicability differences among patients with different types of tumors such as hematological system tumors and lung cancer have not been defined.
Future research directions need to focus on three aspects: conducting large-sample clinical trials to verify the drug's efficacy in different tumor types; exploring sequential therapy regimens of "bone formation-promoting drugs + antiresorptive drugs"; developing individualized medication strategies, and formulating precise treatment plans based on patients' tumor stages and bone metabolism indicators.
FAQ
What is it used for?
+
-
Abaloparatide injection is used to treat osteoporosis (condition in which the bones become thin and weak and break easily) in women who have undergone menopause ('change in life,' end of menstrual periods), who are at high risk of fractures (broken bones) (history of fracture from osteoporosis or multiple risk factors.
How long can you take it?
+
-
You'll likely continue taking the medication as long as it's helping your osteoporosis and you're not having side effects. But the longest you can take Tymlos is up to 2 years. It's not known if the medication is safe or works well in people who take it longer than 2 years since it hasn't been studied.
What are the risks of taking it?
+
-
Adverse effects associated with the use of it may include, but are not limited to, the following: hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain, vertigo.
Is it better than teriparatide?
+
-
The product, a novel synthetic analogue of human parathyroid hormone-related peptide, appears to have better efficacy and safety than teriparatide, which has the same mechanism of action.
Hot Tags: abaloparatide tablet, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale